deltatrials
Active Not Recruiting PHASE2 NCT03449108

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Sponsor: Iovance Biotherapeutics, Inc.

Conditions Bone Sarcoma Dedifferentiated Chondrosarcoma Giant Cell Tumor of Bone Malignancy in Giant Cell Tumor of Bone Malignant Solid Neoplasm Ovarian Carcinosarcoma Platinum-Resistant Ovarian Carcinoma Poorly Differentiated Thyroid Gland Carcinoma Recurrent Osteosarcoma Recurrent Ovarian Carcinoma Refractory Osteosarcoma Soft Tissue Sarcoma Thyroid Gland Anaplastic Carcinoma Thyroid Gland Squamous Cell Carcinoma Triple Negative Breast Cancer Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions Aldesleukin Autologous Tumor Infiltrating Lymphocytes LN-145 Autologous Tumor Infiltrating Lymphocytes LN-145-S1 Cyclophosphamide Fludarabine Ipilimumab Nivolumab Quality-of-Life Assessment Questionnaire Administration
Updated 31 times since 2018 Last updated: Nov 20, 2025 Started: Apr 27, 2018 Primary completion: Apr 30, 2027 Completion: Apr 30, 2027

Listed as NCT03449108, this PHASE2 trial focuses on Bone Sarcoma and Dedifferentiated Chondrosarcoma and remains ongoing. Sponsored by Iovance Biotherapeutics, Inc., it has been updated 31 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Dec 2018 · 5 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jun 2025 · 6 months · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Dec 2025 · 5 months · monthly snapshot~Dec 2025 – present · 4 months · monthly snapshot

Change History

31 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 26 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  7. Sep 2022 — Jun 2023 [monthly]

    Recruiting PHASE2

  8. Dec 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  9. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  10. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  11. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  12. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  13. Feb 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  14. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  15. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  16. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  17. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  18. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  19. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  20. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  21. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  22. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  23. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  24. Jul 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  25. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  26. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Iovance Biotherapeutics, Inc.
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations